SCHEMBL6166791

SCHEMBL6166791

CCCc1sc(COC2CCCCO2)nc1-c1cccc(C(=O)CC(=O)OC(C)(C)C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.36
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
USP30 Q70CQ3 1/20 0.33
FBP1 P09467 1/20 0.33
CREBBP Q92793 2/20 0.32
CPT2 P23786 2/20 0.32
CPT1A P50416 2/20 0.32
CPT1B Q92523 1/20 0.32
TSHR P16473 1/20 0.32
EP300 Q09472 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166605 0.89 CPT2 (0.40) ADORA3ICAM1SELEUSP30CREBBP
SCHEMBL6165033 0.86 ADORA3 (0.36) ADORA3ICAM1SELEUSP30CREBBP
SCHEMBL6163591 0.85 CPT2 (0.35) ADORA3ICAM1SELEUSP30CREBBP
SCHEMBL6168187 0.82 HRH3 (0.36) ICAM1SELEUSP30CREBBPEP300
SCHEMBL6164047 0.79 GABRA5 (0.40) USP30CREBBPEP300MEN1KMT2A
SCHEMBL6165780 0.79 CPT2 (0.39) USP30CPT2CPT1ACPT1BALDH1A1
SCHEMBL6166741 0.79 MLLT1 (0.39) USP30TSHRALDH1A1HPGDMEN1
SCHEMBL6166564 0.78 KDM4C (0.37) ADORA3ICAM1SELEUSP30KDM4C
SCHEMBL5562921 0.77 USP30 (0.37) ICAM1SELEUSP30CREBBPEP300
SCHEMBL6164513 0.77 FFAR1 (0.35) ICAM1SELEUSP30CREBBPEP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 ADORA3 473/4885ICAM1 1627/4885SELE 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.